How Long Does Vyvanse Last? A Complete Prodrug Guide

Vyvanse (lisdexamfetamine) is a prodrug. Controlled studies measured clinical effects at time points through 13 hours in children and 14 hours in adults. What makes Vyvanse distinctive is how it achieves that duration: it is a pharmacologically inactive molecule that your body must convert into the active drug before it works.

This design has consequences that go far beyond just lasting longer. It changes how the medication responds to food, how consistently it works from day to day, and its abuse potential relative to conventional amphetamine formulations. This article explains the pharmacology behind these properties, cited to primary sources.

For background on Adderall IR and XR, see our companion article: How Long Does Adderall Last? IR vs XR. For methylphenidate formulations, see How Long Does Ritalin Last?

---

The prodrug mechanism: why Vyvanse is different

Lisdexamfetamine is d-amphetamine covalently bonded to the amino acid l-lysine. In this bonded form, the molecule is pharmacologically inactive — it cannot bind to dopamine or norepinephrine transporters and has no stimulant effect (Vyvanse FDA label).

After oral administration, intact lisdexamfetamine is absorbed in the small intestine via PEPT1 active carrier transport. The prodrug’s uptake in the gut is independent of stomach acid or pH and is not meaningfully dependent on food. It does not need to be converted in the stomach or intestine before entering the circulation (Pennick, 2010).

Once in the blood, rate-limiting hydrolysis occurs primarily in the cytosol of red blood cells (erythrocytes). Aminopeptidases cleave the bond into L-lysine and active d-amphetamine (Sharman & Pennick, 2014). Inhibitor profiling suggests a metallo-aminopeptidase is involved, although the exact enzyme has not been identified.

This enzymatic conversion is the rate-limiting step in Vyvanse’s pharmacokinetics. No matter how much lisdexamfetamine enters the bloodstream at once, the rate at which active d-amphetamine appears is governed by how fast red blood cells can perform the conversion. The half-life of lisdexamfetamine in whole blood is approximately 1.6 hours (Sharman & Pennick, 2014), which means the prodrug is rapidly consumed but the resulting d-amphetamine is produced gradually and steadily.

This design has three practical consequences:

• Gradual onset: d-Amphetamine levels rise more slowly and consistently than with immediate-release amphetamine, producing a smoother transition into effect.
  • Limited GI pH dependence: Gut uptake does not require stomach acid, and food does not control the prodrug’s carrier transport. Food can still shift the observed active-metabolite peak.
• Reduced abuse potential: Crushing, snorting, or injecting lisdexamfetamine does not produce a faster or more intense effect, because the drug still requires red blood cell conversion regardless of the route of administration.

Research by Jasinski & Krishnan (2009) confirmed the abuse liability profile: at the therapeutically equivalent dose, oral lisdexamfetamine produced no statistically significant drug liking compared to placebo, while equivalent d-amphetamine did.

---

How long Vyvanse lasts in studies

Vyvanse has been studied in controlled laboratory settings that measure clinical effects hour by hour. The reported endpoints describe study populations and measured time points, not a guaranteed duration for one person.

In children: 13 hours

Wigal et al. (2009)

conducted a 13-hour laboratory school study with 117 children ages 6–12 with ADHD. Vyvanse was significantly superior to placebo at every time point from 1.5 to 13 hours post-dose (p<0.005 at each), as measured by attention, deportment, and math performance assessments. 13 hours was the last measurement timepoint in this study.

In adults: 14 hours

Wigal et al. (2010)

extended the duration measurement to adults using a simulated workplace environment. In 105 adults, Vyvanse was significantly superior to placebo at every time point from 2 to 14 hours post-dose (p≤0.0017 at each). This was the first study to demonstrate efficacy of any approved oral stimulant at 14 hours after dosing.

A comprehensive review by Ermer et al. (2016) summarized the relationship between lisdexamfetamine exposure, d-amphetamine appearance, and measured efficacy duration.

---

Pharmacokinetic profile

Sources: Vyvanse FDA label; Ermer et al., 2016; Krishnan & Stark, 2008.

The prodrug lisdexamfetamine itself appears and disappears quickly (tmax ~1 hour, t½ <1 hour). What matters clinically is the d-amphetamine it releases, which peaks later (~3.5–3.8 hours) and has a half-life of approximately 10–11 hours in adults.

A head-to-head study by Dolder et al. (2017) compared equimolar doses of lisdexamfetamine and d-amphetamine IR in 24 healthy volunteers. Both produced similar total d-amphetamine exposure and similar half-lives (~7.9 hours in this younger population), but lisdexamfetamine had a delayed onset of approximately 1 hour. This confirms that the prodrug changes when d-amphetamine appears in the bloodstream but not how it is eliminated — because it is the same molecule once converted.

Repeated-dose studies found minimal accumulation of d-amphetamine at steady state (Krishnan & Stark, 2008; FDA label).

ADHD pharmacokinetic glossary

• Tmax: The time at which a measured plasma concentration reaches its peak.
• Half-life: The time required for the measured concentration to fall by half; it is not the same as felt duration.
• AUC: Area under the concentration–time curve, a measure of total systemic exposure over the sampling period.

Vyvanse: prodrug conversion to active d-amphetamine

---

---

Food effects and flexible dosing

One of the practical advantages of Vyvanse’s prodrug design is its minimal sensitivity to food. Because the rate-limiting step is enzymatic conversion in red blood cells — not absorption from the gut — changes in gastric emptying have a limited effect on the overall timeline.

The FDA label reports that for capsules, a high-fat meal delays d-amphetamine peak by approximately 1 hour (from 3.8 hours fasted to 4.7 hours with food) without meaningfully affecting total exposure or peak concentration. This observed shift does not mean stomach acid controls PEPT1 uptake; it reflects the overall absorption and conversion timeline (Vyvanse FDA label).

In a randomized crossover study, the active d-amphetamine exposure was bioequivalent when capsule contents were consumed in yogurt or orange juice compared with an intact capsule (Ermer et al., 2016). The study supports comparable active exposure across these administration formats, while intact prodrug levels themselves differed.

Flexible administration

The Vyvanse capsule can be opened and its contents mixed with yogurt, water, or orange juice — all confirmed bioequivalent to the intact capsule in a formal study (FDA label). A chewable tablet formulation is also available and delivers equivalent d-amphetamine exposure to the capsule, with a slightly later peak in adults (~4.4 hours vs. ~3.8 hours for capsules) (FDA label).

---

Why it feels different some days

Despite the prodrug mechanism providing more consistent absorption than conventional formulations, day-to-day variability still exists. Here is why.

Urine pH

Once d-amphetamine is released from the prodrug in the blood, it follows the usual amphetamine elimination pathways. Urinary pH affects clearance: acidic urine decreases renal tubular reabsorption and increases excretion, while alkaline urine tends to increase reabsorption. High-dose ascorbic acid (vitamin C) can acidify urine and accelerate active d-amphetamine excretion. This is a post-conversion effect, not a change in PEPT1 absorption.

Age

d-Amphetamine half-life varies by age. In children ages 6–12, it is approximately 8.6–9 hours; in adults, it is about 10–11 hours. Ermer et al. (2013) studied 47 healthy adults aged 55 and older and found that d-amphetamine clearance decreased with age; participants aged 75 and older had later median Tmax and higher exposure than the younger older-adult groups (PMID 23431065). These are cohort observations, not an individual prediction.

Exposure

Lisdexamfetamine shows approximately dose-proportional pharmacokinetics in the studied range: higher administered amounts produce proportionally higher d-amphetamine exposure. This describes a population PK relationship; it does not determine an appropriate amount for any individual (FDA label).

---

How Vyvanse compares to Adderall

Sources: Vyvanse FDA label; Adderall XR FDA label; Adderall IR FDA label. For detailed Adderall pharmacokinetics, see our Adderall guide.

---

Sleep implications

The measured clinical window is distinct from the elimination window. The d-amphetamine released by Vyvanse has a half-life of 10–11 hours in adults, so residual levels can persist after the noticeable clinical effect has faded.

In FDA clinical trials, 27% of adults on Vyvanse reported insomnia compared to 8% on placebo. In children, the rate was 22% versus 3%. The FDA label warns that residual stimulant exposure can be relevant to sleep.

Adding caffeine to a Vyvanse regimen compounds the issue, since caffeine’s own half-life (~5 hours) means afternoon coffee is often still active at bedtime. For a detailed analysis of how stimulant medications and caffeine interact with sleep, see our articles on sleep and ADHD medication and caffeine and ADHD medication.

---

Frequently asked questions

---

References

1. Vyvanse (lisdexamfetamine dimesylate) prescribing information. dailymed.nlm.nih.gov
2. Wigal SB, et al. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with ADHD. Child Adolesc Psychiatry Ment Health. 2009;3(1):17. pmc.ncbi.nlm.nih.gov
3. Wigal SB, et al. Efficacy of lisdexamfetamine dimesylate in adults with ADHD assessed in a randomized, double-blind, placebo-controlled, simulated adult workplace environment. Behav Brain Funct. 2010;6:34. pmc.ncbi.nlm.nih.gov
4. Ermer JC, et al. Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy. Clin Drug Investig. 2016;36:341-356. pubmed.ncbi.nlm.nih.gov
5. Ermer J, et al. Double-blind, placebo-controlled, two-period, crossover trial of lisdexamfetamine pharmacokinetics in healthy older adults. Neuropsychiatr Dis Treat. 2013;9:219-229 (PMID 23431065). pubmed.ncbi.nlm.nih.gov
6. Ermer J, et al. Relative bioavailabilities of lisdexamfetamine and d-amphetamine after mixing with food or drink. Ther Drug Monit. 2016;38(6):769-776 (PMID 27661399). pubmed.ncbi.nlm.nih.gov
7. Dolder PC, et al. Pharmacokinetics and pharmacodynamics of lisdexamfetamine compared with d-amphetamine in healthy subjects. Front Pharmacol. 2017;8:617. pmc.ncbi.nlm.nih.gov
8. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317-327. pmc.ncbi.nlm.nih.gov
9. Sharman J, Pennick M. Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells. Neuropsychiatr Dis Treat. 2014;10:2275-2280. pmc.ncbi.nlm.nih.gov
10. Krishnan S, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin. 2008;24(1):33-40. pubmed.ncbi.nlm.nih.gov
11. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23(4):419-427. pubmed.ncbi.nlm.nih.gov
12. Adderall XR (mixed amphetamine salts ER) prescribing information. dailymed.nlm.nih.gov
13. Adderall (mixed amphetamine salts) prescribing information. dailymed.nlm.nih.gov